on SANOFI-AVENTIS (EPA:SAN)
Sanofi's Infilbray Gains FDA Approval for Type 3 Gaucher Disease Neurological Symptoms
Sanofi's Infilbray, an oral medication, has been approved by the US FDA to treat neurological manifestations of Type 3 Gaucher disease (GD3). This marks a first in addressing the central nervous system (CNS) issues associated with this chronic form of Gaucher disease. GD3 leads to both systemic and neurologic decline.
The approval was based on the LEAP2MONO phase 3 study, which demonstrated Infilbray's superiority over enzyme replacement therapy in improving neurological symptoms. Patients showed significant progress in cognitive and motor functions.
Infilbray's approval is seen as a crucial development for GD3 patients facing limited therapeutic options for neurological symptoms. With prior designations for breakthrough therapy, rare pediatric disease, and fast-track review, Infilbray is set to expand its global regulatory reach in the coming years.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SANOFI-AVENTIS news